Duchenne muscular dystrophy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Duchenne muscular dystrophy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Duchenne muscular dystrophy future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Duchenne muscular dystrophy future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Duchenne muscular dystrophy future or investigational therapies

CDC on Duchenne muscular dystrophy future or investigational therapies

Duchenne muscular dystrophy future or investigational therapies in the news

Blogs on Duchenne muscular dystrophy future or investigational therapies

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Duchenne muscular dystrophy future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Fahimeh Shojaei, M.D.

## Overview[edit | edit source]

Future or investigational therapies for Duchenne muscular dystrophy include gene therapy, creatine monohydrate, myostatin inactivation, cell therapy, and idebenone (antioxidant).

## Future or Investigational Therapies[edit | edit source]

Future or investigational therapies for Duchenne muscular dystrophy include:[1][2][3][4][5]

* Gene therapy
* Injecting microdystrophin genes through recombinant adeno-associated viral (rAAV) vectors
* Creatine monohydrate
* Increases muscle strength
* Myostatin inactivation
* Increase muscle mass and strength
* Cell therapy
* Isolating and transplanting muscle satellite cells as a skeletal muscle progenitor.
* Idebenone (antioxidant)

## References[edit | edit source]

1. ↑ Konieczny P, Swiderski K, Chamberlain JS (May 2013). "Gene and cell-mediated therapies for muscular dystrophy". Muscle Nerve. 47 (5): 649–63. doi:10.1002/mus.23738. PMC 4077844. PMID 23553671.
2. ↑ Walter MC, Lochmüller H, Reilich P, Klopstock T, Huber R, Hartard M, Hennig M, Pongratz D, Müller-Felber W (May 2000). "Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study". Neurology. 54 (9): 1848–50. PMID 10802796.
3. ↑ Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS (November 2002). "Functional improvement of dystrophic muscle by myostatin blockade". Nature. 420 (6914): 418–21. doi:10.1038/nature01154. PMID 12459784.
4. ↑ Cerletti M, Jurga S, Witczak CA, Hirshman MF, Shadrach JL, Goodyear LJ, Wagers AJ (July 2008). "Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles". Cell. 134 (1): 37–47. doi:10.1016/j.cell.2008.05.049. PMC 3665268. PMID 18614009.
5. ↑ Buyse GM, Voit T, Schara U, Straathof C, D'Angelo MG, Bernert G, Cuisset JM, Finkel RS, Goemans N, McDonald CM, Rummey C, Meier T (May 2015). "Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial". Lancet. 385 (9979): 1748–1757. doi:10.1016/S0140-6736(15)60025-3. PMID 25907158. Vancouver style error: initials (help)

Template:WH Template:WS